Navigation Links
MacuSight(TM) Announces Positive Initial Results From Phase 1 Study of Sirolimus in Diabetic Macular Edema
Date:10/1/2007

also delighted the drug appeared so effective by a simple subconjunctival injection, a route of administration that is able to decrease the risk and treatment burden to patients and physicians alike. As a result, we can confidently proceed with our clinical development of sirolimus as a product delivered via subconjunctival injection."

With regard to safety and tolerability, the study showed no evidence of increased intraocular pressure or inflammatory response to treatment. MacuSight intends to complete its collection and analysis of all data from this trial and present final findings later this year.

"From a patient treatment standpoint, the study findings related to the safety and biological activity of sirolimus administered through subconjunctival injection are very exciting," stated Pravin U. Dugel, M.D., clinical instructor, vitreoretinal diseases and surgery, department of ophthalmology, University of Arizona, partner at Retinal Consultants of Arizona in Phoenix, Arizona, and the study's lead investigator. "By offering both physicians and patients significant benefits in the way of reduced invasiveness, safety and ease of administration, the subconjunctival injection has the potential to dramatically improve the current DME treatment paradigm."

Additionally, MacuSight has completed enrollment of its second Phase 1 trial which is examining its same proprietary sirolimus formulation in patients with exudative age-related macular degeneration. Results from this second trial are expected to be presented during the first half of 2008.

About Sirolimus

Sirolimus, originally known as rapamycin, is a highly-potent, broad-acting compound that has demonstrated the ability to combat disease through multiple mechanisms of action including immunosuppressive, anti-angiogenic, anti-migratory, anti-proliferative, anti-fibrotic and anti-permeability activity. Based on the versatility associated with these multiple mechanisms of action, MacuSight
'/>"/>

SOURCE MacuSight, Inc.
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Sygnis Pharma AG announces date for presentation of clinical results
3. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
5. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
6. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
7. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
8. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
9. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
10. Protox Announces Positive Clinical Data from Prostate Cancer Study
11. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/16/2009)... CareCentrix, Inc ., the nation,s leading provider ... that it has been awarded Health Utilization Accreditation ... organization that establishes quality standards for the health ... trained, qualified clinical personnel conduct and oversee the ... appeals process is in place, and that medical ...
(Date:12/16/2009)... Dec. 16 /PRNewswire/ -- Sanofi ... Group, announced today that it has entered ... Syntiron to develop and commercialize its prophylactic ... Staphylococcus aureus or MRSA. MRSA ... humans, sometimes referred to as multidrug-resistant ...
(Date:12/16/2009)... Illinois Disappointed By Senate Vote Against Lower Prescription ... -- The U.S. Senate on Tuesday night rejected ... Care Act that would help make prescription drugs ... legal importation of lower priced drugs from abroad. ... sponsored by Senators Dorgan, Snowe, McCain, Grassley and ...
Breaking Medicine Technology:CareCentrix Receives URAC Health Utilization Management Accreditation 2Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 2Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 3Sanofi Pasteur Obtains License from Syntiron to Develop & Commercialize Vaccine to Prevent Staphylococcus Infections 4AARP Illinois Key Vote News Alert 2Sundia Appoints Charles D Maher as Senior Vice President of Sales and Marketing 14481 1Sundia Appoints Charles D Maher as Senior Vice President of Sales and Marketing 14481 2Department of Energy Grants BlueFire Approval for Site Change 14479 1Department of Energy Grants BlueFire Approval for Site Change 14479 2Department of Energy Grants BlueFire Approval for Site Change 14479 3Department of Energy Grants BlueFire Approval for Site Change 14479 4Cynosure to Announce Third Quarter 2009 Financial Results on October 27 5509 1Cynosure to Announce Third Quarter 2009 Financial Results on October 27 5509 2
... tolerance observed in Genotype,1 patients support development ... 21, 2007 /PRNewswire/ -- Intarcia Therapeutics,Inc., a ... of final results from a Phase 2 ... and ribavirin to,omega interferon alone in treatment-naive ...
... Function and Treatment of Anxious,and Painful Physical ... -- Data,suggest that patients with generalized anxiety ... improved,ability to perform everyday activities at home, ... pill. These improvements in global,functioning were the ...
Other Medicine Technology:Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 2Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 3Intarcia Therapeutics Announces Presentation of Final Results From,a Phase 2 Combination Study for the Treatment of Hepatitis C at the,Digestive Disease Week Conference 4Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 2Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 3Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 4Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 5Data Suggest Cymbalta Improved Functioning in Patients with,Generalized Anxiety Disorder 6
(Date:12/17/2009)... service gets businesses listed on search engines like Google Local and ... affordable Web presence with SEO Local Registration service offered by New ... ... LA (PRWEB) December 17, 2009 -- In order to be competitive ... website or a listing on a local map section in a ...
(Date:12/17/2009)... law firm, litigators of complex personal injury and insurance cases, recognized ... ... Tulsa, OK (Lexis Nexis) December 17, 2009 -- Jody ... of experience handling personal injury and insurance coverage disputes, has been ... attorneys in the state of Oklahoma for 2009-2010., , ,Only five ...
(Date:12/16/2009)... Calif., Dec. 17 If proposed health ... standards in the employer-based insurance system. Approximately 18.4 ... age of 65 rely upon employer-based insurance for ... and Senate versions of reform legislation entail specific ... majority of employees work for firms that currently ...
(Date:12/16/2009)... Dec. 16 Smart Balance, Inc. (Nasdaq: ... has authorized a two-year stock repurchase program of up ... repurchase program demonstrates the confidence we have in the ... deliver long-term value for all of our shareholders, while ... said Stephen Hughes, Smart Balance, Inc. Chairman and Chief ...
(Date:12/16/2009)... December 16, 2009 -- Every year in the United ... 57,000 patients die of the disease, making it the ... after lung cancer. , As researchers and clinicians fervently ... simultaneously generating thousands of studies producing more and more ... of cancer and genetics at Case Western Reserve University ...
Breaking Medicine News(10 mins):Health News:New Orleans Based Internet Marketing Is Helping Small Businesses Get a Chance to Shine On the Web 2Health News:Jody Nathan, Highly Regarded Tulsa Attorney, Named to 2009 Oklahoma Super Lawyers List 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 2Health News:How National Health Reform Proposals Would Affect Employer-Based Plans in California 3Health News:Smart Balance Authorizes Stock Repurchase Program 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 2Health News:New England Journal of Medicine publishes CWRU review of the 'molecular basis of colorectal cancer' 3
... Episodes of the Oprah Winfrey ... Show on November 1 and November 5 -, SILVER SPRING, ... has a direct effect our waistlines, but how aware are we,that ... quality of,sleep actually impact our body,s physical age? Discovery Health,s chief,medical ...
... five,successful years of steady growth, ReBuilder Medical Technologies, ... celebrating five years of,continued operations by shipping out ... 100,000 orders by the end of 2008., ... for Diabetic Peripheral Neuropathy has been a steady,winner ...
... can help complement a healthy diet and lifestyle, but,consumers ... says the,new edition of a Harvard Medical School report, ... know., The immune system defends the body against ... claim their products,"support" immunity. But so far, there is ...
... Palmer with critical access control features and ... support for bandwidth-intensive applications, WALTHAM, Mass. ... Colubris Networks, the leading global provider of,intelligent wireless LANs ... College of Chiropractic, the largest,chiropractic college in the world, ...
... shows that religion and spirituality are linked to positive ... on people with life threatening diseases. A new study ... many individuals with disabilities adjust to their impairments and ... the study, persons facing impending death may use religion ...
... the scientific symposium of the Cardiovascular Research Foundation (CRF), show ... (SSO 2 ) can reduce the amount of damaged heart ... or restoration of blood flow to the heart with angioplasty ... of infarction, or damaged heart muscle caused by the death ...
Other Medicine News:Health News:Dr. Oz and Dr. Roizen Prove That Aging Is Actually Reversible in You: Staying Young on Discovery Health 2Health News:Dr. Oz and Dr. Roizen Prove That Aging Is Actually Reversible in You: Staying Young on Discovery Health 3Health News:ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment 2Health News:ReBuilder Medical Technologies, Inc. Celebrates Five Years and 50,000th Shipment 3Health News:Harvard Medical School: Healthy Lifestyle Will Boost Your Immune System Better Than a Handful of Supplements 2Health News:Palmer College of Chiropractic Selects Colubris Networks to Provide Wireless Infrastructure at Three U.S. Campuses 2Health News:Palmer College of Chiropractic Selects Colubris Networks to Provide Wireless Infrastructure at Three U.S. Campuses 3Health News:Religion and healthcare should mix, MU study says 2
ASAP™ Automated Biopsy System with Channel Cut™ Needle....
The Easy Core Biopsy Device offers exceptional performance in automated core biopsy, and provides excellent ergonomics and increased notch size....
Incontinence Pessaries...
Incontinence Pessaries...
Medicine Products: